The U.S. Food and Drug Administration (FDA) has approved a test that helps in assessing the risk of tumor recurrence and long-term survival for patients with relatively high-risk breast cancer. The TOP2A FISH pharmDx is the first approved device to test for the TOP2A (topoisomerase 2 alpha) gene in cancer patients.
The TOP2A gene plays a role in DNA replication. Changes in the TOP2A gene in breast cancer cells mean there is an increased likelihood that the tumor will recur or that long-term survival will be decreased.
The test is suitable for breast cancer patients who are premenopausal or for whom tumor …read more